Xtant Medical (XTNT) to Release Quarterly Earnings on Thursday

Xtant Medical (NYSEAMERICAN:XTNT) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Xtant Medical to post earnings of ($0.0049) per share and revenue of $30.75 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Xtant Medical Stock Performance

Shares of XTNT opened at $0.59 on Wednesday. The firm has a market cap of $82.54 million, a P/E ratio of 59.02 and a beta of -0.30. Xtant Medical has a twelve month low of $0.34 and a twelve month high of $0.95. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.06 and a current ratio of 2.21. The firm’s 50 day moving average price is $0.65 and its two-hundred day moving average price is $0.67.

Analysts Set New Price Targets

Separately, BTIG Research cut their price objective on shares of Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Xtant Medical currently has an average rating of “Buy” and a consensus target price of $1.50.

Hedge Funds Weigh In On Xtant Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of Xtant Medical during the second quarter valued at $26,000. Wiregrass Investment Management LLC acquired a new stake in Xtant Medical in the fourth quarter valued at $81,000. Mink Brook Asset Management LLC increased its holdings in Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares during the period. Renaissance Technologies LLC raised its position in Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after purchasing an additional 205,945 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after buying an additional 104,159 shares during the period. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.